Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Oct 30, 2022 1:18pm
167 Views
Post# 35058575

RE:anyone else hearing

RE:anyone else hearingIf something like that is imminent then one must wonder whether no deals have been allowed to happen during the "negotiation" period. In other words, would the pharma require Bioasis to enter no agreements until buyout terms are "negotiated," a word that I put in quotation markes for obvious reasons.

Imagine, a deal for all of Bioasis for less than what xB3-001 is worth.

Like I've been saying, watch out for the AGM information circular with an agenda asking for a management mandate to do whatever they want.

Black helicopters? 

whoop, whoop, whoop, whoop, whoop, whoop...

jd
<< Previous
Bullboard Posts
Next >>